| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Hearing Loss, Sensorineural | D006319 | 8 associated lipids |
| Otitis Media | D010033 | 12 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- FEMS Immunol. Med. Microbiol. (1)
- J. Antimicrob. Chemother. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Pilotto A et al. | Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. | 1999 | J. Gastroenterol. Hepatol. | pmid:10355512 |
| Jacoby EB and Porter KB | Helicobacter pylori infection and persistent hyperemesis gravidarum. | 1999 | Am J Perinatol | pmid:10355915 |
| Fost DA et al. | Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. | 1999 | J. Allergy Clin. Immunol. | pmid:10359882 |
| Gooch WM et al. | Loracarbef versus clarithromycin in children with acute otitis media with effusion. | 1999 | Clin Ther | pmid:10363736 |
| Moshkowitz M et al. | The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. | 1999 | J Am Geriatr Soc | pmid:10366173 |
| Wimsatt JH et al. | Clarithromycin pharmacokinetics in the desert tortoise (Gopherus agassizii). | 1999 | J. Zoo Wildl. Med. | pmid:10367642 |
| Iida H et al. | Hypoglycemia induced by interaction between clarithromycin and disopyramide. | 1999 | Jpn Heart J | pmid:10370402 |
| Bhasin DK et al. | Helicobacter pylori eradication: comparison of three treatment regimens in India. | 1999 | J. Clin. Gastroenterol. | pmid:10372934 |
| Behrens R et al. | Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial. | 1999 | Arch. Dis. Child. | pmid:10373140 |
| Masa K et al. | Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs. | 1999 | Biol. Pharm. Bull. | pmid:10375172 |
| Bamford JT et al. | Effect of treatment of Helicobacter pylori infection on rosacea. | 1999 | Arch Dermatol | pmid:10376693 |
| Alvarez-Elcoro S and Enzler MJ | The macrolides: erythromycin, clarithromycin, and azithromycin. | 1999 | Mayo Clin. Proc. | pmid:10377939 |
| Vakil N | Treatment of H. pylori infection: the reality. | 1998 Mar-Apr | Yale J Biol Med | pmid:10378357 |
| Delle Cave M et al. | Seven days of ranitidine bismuth citrate plus two antimicrobials for Helicobacter pylori eradication. | 1999 | Ital J Gastroenterol Hepatol | pmid:10379492 |
| Schubert ML | H. pylori and nonulcer dyspepsia: not guilty as charged. | 1999 | Gastroenterology | pmid:10381939 |
| Realdi G et al. | Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. | 1999 | Helicobacter | pmid:10382124 |
| Schwartz HI et al. | Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. | 1999 | Helicobacter | pmid:10382126 |
| Hoellman DB et al. | Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. | 1999 | J. Antimicrob. Chemother. | pmid:10382885 |
| Steele-Moore L et al. | In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. | 1999 | Antimicrob. Agents Chemother. | pmid:10383373 |
| Huang J and Hunt RH | The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383500 |
| Miwa H et al. | Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383502 |
| Ducóns JA et al. | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383507 |
| Calvet X et al. | Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383508 |
| Sieg A et al. | Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383519 |
| Grimley CE et al. | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383520 |
| Houben MH et al. | Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383522 |
| Tomiyama Y et al. | [The combination therapy of clarithromycin and sparfloxacin for pulmonary Mycobacterium gordonae infection]. | 1999 | Kekkaku | pmid:10386036 |
| Stewart AK et al. | Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. | 1999 | Blood | pmid:10391696 |
| Raderer M et al. | Successful symptomatic management of a patient with Ménétrier's disease with long-term antibiotic treatment. | 1999 Jul-Aug | Digestion | pmid:10394031 |
| Tsukamoto T et al. | Biofilm in complicated urinary tract infection. | 1999 | Int. J. Antimicrob. Agents | pmid:10394976 |
| Hafner R et al. | Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. | 1999 | J. Infect. Dis. | pmid:10395860 |
| Inoue M et al. | [Susceptibilities of Enterococcus faecium, PRSP and MRSA to RP59500 and their correlations with those to other drugs]. | 1999 | Jpn J Antibiot | pmid:10396687 |
| Lasko B et al. | Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized study. The Canadian Sinusitis Study Group. | 1998 | J. Int. Med. Res. | pmid:10399110 |
| Horgan SE et al. | Use of a low nutrient culture medium for the identification of bacteria causing severe ocular infection. | 1999 | J. Med. Microbiol. | pmid:10403423 |
| Mera R et al. | Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed. | 1999 | J. Clin. Gastroenterol. | pmid:10405232 |
| Katsura Y et al. | Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4-furylthiazoles. | 1999 | J. Med. Chem. | pmid:10425101 |
| Grimm KJ | Treatment of Helicobacter pylori infection in functional dyspepsia. | 1999 | J Fam Pract | pmid:10428242 |
| Johnson MM et al. | Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. | 1999 | Antimicrob. Agents Chemother. | pmid:10428903 |
| Credito KL et al. | Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. | 1999 | Antimicrob. Agents Chemother. | pmid:10428930 |
| Kyzekova J and Mour J | The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. | 1999 May-Jun | Hepatogastroenterology | pmid:10430396 |
| Owen RJ et al. | Effect of clarithromycin and omeprazole therapy on the diversity and stability of genotypes of Helicobacter pylori from duodenal ulcer patients. | 1999 | Microb. Drug Resist. | pmid:10432275 |
| Baena DÃez JM et al. | [Are 5 days of omeprazole plus 2 antibiotics enough for eradication of H. pylori? Comments on sample size]. | 1999 | Rev Clin Esp | pmid:10432821 |
| Schmitt H et al. | Successful treatment of pulmonary Mycobacterium xenopi infection in a natural killer cell-deficient patient with clarithromycin, rifabutin, and sparfloxacin. | 1999 | Clin. Infect. Dis. | pmid:10433574 |
| Cohn DL et al. | A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS. | 1999 | Clin. Infect. Dis. | pmid:10433575 |
| Lipsky BA et al. | Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin. | 1999 | Clin Ther | pmid:10440620 |
| Shimada N et al. | [A case of acute renal failure with rhabdomyolysis caused by the interaction of theophylline and clarithromycin]. | 1999 | Nihon Jinzo Gakkai Shi | pmid:10441997 |
| Bazzoli F | My approach to Helicobacter pylori eradication. | 1999 | Eur J Gastroenterol Hepatol | pmid:10443911 |
| Ali' A et al. | A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. | 1999 | Am. J. Gastroenterol. | pmid:10445583 |
| Hewitt RG et al. | Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. | 1999 | AIDS | pmid:10449290 |
| Enroth H et al. | Occurence of resistance mutation and clonal expansion in Helicobacter pylori multiple-strain infection: a potential risk in clarithromycin-based therapy. | 1999 | Clin. Infect. Dis. | pmid:10451171 |